23ME-00610, a genetically informed, first-in-class antibody targeting CD200R1 to enhance antitumor T cell function

References

• Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Cancer Cell. 2020;37(4):443–10. doi:10.1016/j.ccell.2020.03.017.
   PubMed Web of Science ®Google Scholar
• Wright GJ, Cherwinski H, Foster-Cuevas M, Brooke G, Puklavec MJ, Bigler M, Song Y, Jenmalm M, Gorman D, McClanahan T, et al. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol. 2003;171(6):3034–3046. doi:10.4049/jimmunol.171.6.3034.
   PubMed Web of Science ®Google Scholar
• Rijkers ES, de Ruiter T, Baridi A, Veninga H, Hoek RM, Meyaard L. The inhibitory CD200R is differentially expressed on human and mouse T and B lymphocytes. Mol Immunol. 2008;45(4):1126–1135. doi:10.1016/j.molimm.2007.07.013.
   PubMed Web of Science ®Google Scholar
• Rygiel TP, Meyaard L. CD200R signaling in tumor tolerance and inflammation: a tricky balance. Curr Opin Immunol. 2012;24(2):233–238. doi:10.1016/j.coi.2012.01.002.
   PubMed Web of Science ®Google Scholar
• Mihrshahi R, Barclay AN, Brown MH. Essential roles for Dok2 and RasGAP in CD200 receptor-mediated regulation of human myeloid cells. J Immunol. 2009;183(8):4879–4886. doi:10.4049/jimmunol.0901531.
   PubMed Web of Science ®Google Scholar
• Zhang S, Cherwinski H, Sedgwick JD, Phillips JH. Molecular mechanisms of CD200 inhibition of mast cell activation. J Immunol. 2004;173(11):6786–6793. doi:10.4049/jimmunol.173.11.6786.
   PubMed Web of Science ®Google Scholar
• Misstear K, Chanas SA, Rezaee SAR, Colman R, Quinn LL, Long HM, Goodyear O, Lord JM, Hislop AD, Blackbourn DJ. Suppression of antigen-specific T cell responses by the Kaposi’s sarcoma-associated herpesvirus viral OX2 protein and its cellular orthologue, CD200. J Virol. 2012;86(11):6246–6257. doi:10.1128/JVI.07168-11.
   PubMed Web of Science ®Google Scholar
• Herbrich S, Baran N, Cai T, Weng C, Aitken MJL, Post SM, Henderson J, Shi C, Havranek O, Richard-Carpentier G, et al. Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML. J ImmunoTher Cancer. 2021;9(7):e002968. doi:10.1136/jitc-2021-002968.
   PubMed Web of Science ®Google Scholar
• Shafiei-Jahani P, Helou DG, Hurrell BP, Howard E, Quach C, Painter JD, Galle-Treger L, Li M, Loh YHE, Akbari O. CD200–CD200R immune checkpoint engagement regulates ILC2 effector function and ameliorates lung inflammation in asthma. Nat Commun. 2021;12(1):2526. doi:10.1038/s41467-021-22832-7.
   PubMed Web of Science ®Google Scholar
• Heilbron K, Mozaffari SV, Vacic V, Yue P, Wang W, Shi J, Jubb AM, Pitts SJ, Wang X. Advancing drug discovery using the power of the human genome. J Pathol. 2021;254(4):418–429. doi:10.1002/path.5664.
   PubMed Web of Science ®Google Scholar
• Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, et al. Defining T cell states associated with response to checkpoint immunotherapy in Melanoma. Cell. 2018;175(4):998–1013 e20. doi:10.1016/j.cell.2018.10.038.
   PubMed Web of Science ®Google Scholar
• Goldstein R, Hanley C, Morris J, Cahill D, Chandra A, Harper P, Chowdhury S, Maher J, Burbridge S. Clinical investigation of the role of interleukin-4 and interleukin-13 in the evolution of prostate cancer. Cancers (Basel). 2011;3(4):4281–4293. doi:10.3390/cancers3044281.
   PubMedGoogle Scholar
• Blom LH, Martel BC, Larsen LF, Hansen CV, Christensen MP, Juel-Berg N, Litman T, Poulsen LK. The immunoglobulin superfamily member CD200R identifies cells involved in type 2 immune responses. Allergy. 2017;72(7):1081–1090. doi:10.1111/all.13129.
   PubMed Web of Science ®Google Scholar
• Wang C, Thudium KB, Han M, Wang X-T, Huang H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2(9):846–856. doi:10.1158/2326-6066.CIR-14-0040.
   PubMed Web of Science ®Google Scholar
• Selby MJ, Engelhardt JJ, Johnston RJ, Lu L-S, Han M, Thudium K, Yao D, Quigley M, Valle J, Wang C, et al. Preclinical development of ipilimumab and nivolumab combination immunotherapy: mouse tumor models, in vitro functional studies, and cynomolgus macaque toxicology. PLos One. 2016;11(9):e0161779. doi:10.1371/journal.pone.0161779.
   PubMed Web of Science ®Google Scholar
• Crown_Bioscience. MuBase. 2022.
   Google Scholar
• Keytruda (pembrolizumab). Prescribing information. Merck. 2022 [ cited 2022; Available from: https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf.
   Google Scholar
• Opdivo (nivolumab). Prescribing information. Bristol-Myers Squibb. 2022 [ cited 2022; Available from: https://packageinserts.bms.com/pi/pi_opdivo.pdf.
   Google Scholar
• Yervoy (ipilimumab). Prescribing information. Bristol-Myers Squibb. 2022 [ cited 2022; Available from: https://packageinserts.bms.com/pi/pi_yervoy.pdf.
   Google Scholar
• Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018;118(1):9–16. doi:10.1038/bjc.2017.434.
   PubMed Web of Science ®Google Scholar
• Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, Floratos A, Sham PC, Li MJ, Wang J, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47(8):856–860. doi:10.1038/ng.3314.
   PubMed Web of Science ®Google Scholar
• Ochoa D, Karim M, Ghoussaini, Hulcoop DG, McDonagh EM, Dunham I. Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs. Nat Rev Drug Discov. 2022;21(8):551. doi:10.1038/d41573-022-00120-3.
   PubMed Web of Science ®Google Scholar
• Sayaman RW, Saad M, Thorsson V, Hu D, Hendrickx W, Roelands J, Porta-Pardo E, Mokrab Y, Farshidfar F, Kirchhoff T, et al. Germline genetic contribution to the immune landscape of cancer. Immunity. 2021;54(2):367–386 e8. doi:10.1016/j.immuni.2021.01.011.
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Lanasa MC, Farber C, Pandey M, Whelden M, Faas SJ, Ulery T, Kukreja A, Li L, Bedrosian CL, et al. Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200. J ImmunoTher Cancer. 2019;7(1):227. doi:10.1186/s40425-019-0710-1.
   PubMed Web of Science ®Google Scholar
• Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM, Blom B, Homola ME, Streit WJ, Brown MH, et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science. 2000;290(5497):1768–1771. doi:10.1126/science.290.5497.1768.
   PubMed Web of Science ®Google Scholar
• Wang X, Zha H, Wu W, Yuan T, Xie S, Jin Z, Long H, Yang F, Wang Z, Zhang A, Gao J. CD200(+) cytotoxic T lymphocytes in the tumor microenvironment are crucial for efficacious anti-PD-1/PD-L1 therapy. Sci Transl Med, 2023. 15(679): p. eabn5029.
   PubMed Web of Science ®Google Scholar
• Kearney CJ, Vervoort SJ, Hogg SJ, Ramsbottom KM, Freeman AJ, Lalaoui N, Pijpers L, Michie J, Brown KK, Knight DA, et al. Tumor immune evasion arises through loss of TNF sensitivity. Sci Immunol. 2018;3(23):3(23. doi:10.1126/sciimmunol.aar3451.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006;6(11):836–848. doi:10.1038/nri1961.
   PubMed Web of Science ®Google Scholar